Prothena’s 2016 2nd quarter results support advancement of multiple clinical development programs

Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development and commercialisation of novel protein immunotherapies, today reported financial results for the second quarter and first six months of 2016. In addition, the Company provided an update on its R&D programs and 2016 financial guidance.

Click on this link for more information.